ARCHIVES
Diastolic Blood Pressure Normalization in Concurrent Type 2 Diabetes and Hypertension: Outcomes of an Ayurvedic Panchakarma Multimodal Protocol — A Retrospective Analysis from Virar, Maharashtra
1 MD and CEO, Vaidya Sane Ayurved Laboratories Limited, Maharashtra, India. 2 Head Medical Operations, Vaidya Sane Ayurved Laboratories Limited, Maharashtra, India. 3 Chief Medical Officer, Vaidya Sane Ayurved Laboratories Limited, Maharashtra, India. 4 Zonal Medical Head, Madhavbaug Clinics, Maharashtra, India. 5 Clinic Head, Madhavbaug Virar (West) Branch, Thane, Maharashtra, India.
Published Online: January-April 2026
Pages: 13-20
Background: Diastolic hypertension is a prevalent and clinically underappreciated complication of type 2 diabetes mellitus (T2DM), directly mediating nephropathy progression, left ventricular diastolic dysfunction, and cardiovascular mortality. Conventional antidiabetic protocols rarely address diastolic blood pressure (DBP) as a primary outcome. Ayurvedic Panchakarma-based multimodal protocols have shown promise in glycemic management, but their effect on diastolic hypertension in T2DM has not been systematically examined. Objectives: To evaluate the effect of the CDC Ayurvedic multimodal protocol — comprising BMI-stratified Panchakarma (CDC-SP, CDC-KP, DM-HTN), Prameha diet, and individualized herbal therapy — on diastolic blood pressure as a primary cardiovascular outcome, alongside glycemic, hemodynamic, and anthropometric parameters in T2DM patients. Methods: Retrospective observational study of 44 T2DM patients (after exclusion of one patient with incomplete data) treated at Madhavbaug Clinics, Virar (West) branch, Thane district, Maharashtra. Three protocol arms were included: CDC-SP (BMI ≥23, n=29), CDC-KP (BMI <23, n=7), and DM-HTN protocol (n=8). Mean follow-up was 117 ± 77 days (median 110 days) — the longest across comparable CDC clinic cohorts. Paired t-tests and Pearson correlations were used for analysis. Results: Baseline DBP was 91.02 ± 9.65 mmHg — 62.8% of patients had Stage 2 diastolic hypertension (DBP ≥90 mmHg) and 14.0% had DBP ≥100 mmHg. Post-intervention DBP declined significantly to 85.09 ± 8.39 mmHg (Δ −5.93 ± 7.85 mmHg, −6.1%, p<0.001). Of the 27 patients with baseline DBP ≥90 mmHg, 15 (55.6%) achieved normalization to <90 mmHg post-treatment. A strong inverse correlation was observed between baseline DBP and magnitude of DBP reduction (r=−0.557, p=0.0001), indicating that the most hypertensive patients derived the greatest benefit. SBP reduced from 133.19 to 124.79 mmHg (Δ −8.40 mmHg, p<0.001), with the proportion of patients achieving SBP <130 mmHg rising from 37.2% to 62.8%. Simultaneously, HbA1c declined from 9.86 ± 1.87% to 8.26 ± 1.63% (Δ −1.60%, p<0.001), RBS by −68.7 mg/dL (p<0.001), and heart rate by −7.17 bpm (p<0.001). The CDC-SP arm showed the most robust outcomes across all parameters (all p<0.01). The CDC-KP arm showed no significant improvement in any parameter, likely due to underpowering (n=7). A notable CKD comorbid patient achieved HbA1c reduction from 9.8% to 5.7% with concurrent DBP normalization (80→68 mmHg). Conclusion: This study demonstrates that a structured Ayurvedic multimodal protocol produces clinically significant diastolic blood pressure normalization in T2DM patients with concurrent hypertension, with 55.6% of diastolic hypertensives achieving DBP <90 mmHg — a threshold with direct implications for nephropathy and cardiovascular risk. The baseline DBP-response correlation suggests that this protocol offers the greatest hemodynamic benefit to the most severely hypertensive patients, aligning with the Ayurvedic principle of titrating Shodhana intensity to the degree of Srotovarodha.
